Form 8-K - Current report:
SEC Accession No. 0001213900-25-063479
Filing Date
2025-07-14
Accepted
2025-07-14 08:06:17
Documents
14
Period of Report
2025-07-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0248754-8k_ostherap.htm   iXBRL 8-K 45426
2 PRESS RELEASE ISSUED BY OS THERAPIES INCORPORATED ON JULY 14, 2025 ea024875401ex99-1_ostherap.htm EX-99.1 15401
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3770
  Complete submission text file 0001213900-25-063479.txt   244010

Data Files

Seq Description Document Type Size
4 XBRL LABEL FILE ostx-20250711_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE ostx-20250711_pre.xml EX-101.PRE 22364
6 XBRL SCHEMA FILE ostx-20250711.xsd EX-101.SCH 3023
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0248754-8k_ostherap_htm.xml XML 3811
Mailing Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850
Business Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850 410-297-7793
OS Therapies Inc (Filer) CIK: 0001795091 (see all company filings)

EIN.: 825118368 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42195 | Film No.: 251120187
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)